ketoprofen / omeprazole (Axorid)

following a full submission 

ketoprofen/omeprazole (Axorid®) is not recommended for use within NHS Scotland for the symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers, duodenal ulcers and gastroduodenal erosions in whom continued treatment with ketoprofen is essential. 
 
Studies in healthy volunteers demonstrated the bioequivalence of this combination product to the reference products, modified release ketoprofen and omeprazole. 
 
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
 
The licence holder has indicated their intention to resubmit.